Plasma Powerhouse

Plasma is the liquid part of human blood that acts as the body’s superhighway, transporting essential elements that sustain healthy functioning, including blood cells, nutrients and, notably, proteins. Serving as the underlying supply chain to all organs, plasma is the source of therapeutics for multiple rare and chronic diseases, is used for emergencies, surgeries and preventive medicine – and the key to enhanced quality of life for many patients. 

Our evolving understanding of the universe of circulating plasma proteins, the plasma proteome, has led to critical scientific advances and therapies that enable patients with chronic plasma protein deficiencies to enjoy healthier, longer and more productive lives. 

We continually refine and advance our treatments, including immunoglobulins for primary and secondary immunodeficiencies, albumin for blood expansion in emergency and surgical medicine, and alpha-1 antitrypsin, indicated in respiratory patients to treat alpha-1 antitrypsin deficiency, among many others. We maintain the highest standards throughout the plasma journey, from collecting plasma to delivering treatments to patients. 

Using advanced AI, bioanalytics and technology platforms such as those from our Alkahest subsidiary, we explore plasma at the deepest level of discovery.  We are specifically studying the makeup and levels of plasma proteins, examining the full range of the plasma proteome to understand how proteins shift over time with age and illness, and how this can potentially offer unique insights to develop transformative therapies. 

An example of this work is our pioneering ‘Chronos-PD’ project. This initiative aims to discover early biomarkers of Parkinson’s disease (PD) to inform the development of new diagnostic and early therapeutic approaches for this neurological condition that affects more than 6 million people worldwide.